CA3231001A1 - Methods for treating neurogenerative diseases - Google Patents
Methods for treating neurogenerative diseases Download PDFInfo
- Publication number
- CA3231001A1 CA3231001A1 CA3231001A CA3231001A CA3231001A1 CA 3231001 A1 CA3231001 A1 CA 3231001A1 CA 3231001 A CA3231001 A CA 3231001A CA 3231001 A CA3231001 A CA 3231001A CA 3231001 A1 CA3231001 A1 CA 3231001A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrimidin
- chloro
- amine
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163260944P | 2021-09-07 | 2021-09-07 | |
| US63/260,944 | 2021-09-07 | ||
| PCT/US2022/075969 WO2023039370A1 (en) | 2021-09-07 | 2022-09-06 | Methods for treating neurogenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3231001A1 true CA3231001A1 (en) | 2023-03-16 |
Family
ID=85506888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3231001A Pending CA3231001A1 (en) | 2021-09-07 | 2022-09-06 | Methods for treating neurogenerative diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240374602A1 (https=) |
| EP (1) | EP4398988A4 (https=) |
| JP (1) | JP2024533264A (https=) |
| CN (1) | CN118401243A (https=) |
| CA (1) | CA3231001A1 (https=) |
| MX (1) | MX2024002887A (https=) |
| WO (1) | WO2023039370A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO2004065392A1 (en) * | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2012012656A2 (en) * | 2010-07-21 | 2012-01-26 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
| CN115209955A (zh) * | 2019-12-12 | 2022-10-18 | Ptc医疗公司 | 治疗家族性自主神经功能障碍的化合物 |
-
2022
- 2022-09-06 MX MX2024002887A patent/MX2024002887A/es unknown
- 2022-09-06 WO PCT/US2022/075969 patent/WO2023039370A1/en not_active Ceased
- 2022-09-06 CA CA3231001A patent/CA3231001A1/en active Pending
- 2022-09-06 EP EP22868238.1A patent/EP4398988A4/en active Pending
- 2022-09-06 US US18/689,680 patent/US20240374602A1/en active Pending
- 2022-09-06 JP JP2024514643A patent/JP2024533264A/ja active Pending
- 2022-09-06 CN CN202280074008.5A patent/CN118401243A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4398988A4 (en) | 2025-07-09 |
| JP2024533264A (ja) | 2024-09-12 |
| EP4398988A1 (en) | 2024-07-17 |
| CN118401243A (zh) | 2024-07-26 |
| WO2023039370A1 (en) | 2023-03-16 |
| US20240374602A1 (en) | 2024-11-14 |
| MX2024002887A (es) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022169864A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US12398140B2 (en) | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | |
| WO2020167628A1 (en) | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | |
| US20250382305A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| WO2022169868A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| EP3402793A1 (en) | Pyridazine derivatives as eaat2 activators | |
| JP2025133750A (ja) | 家族性自律神経失調症を処置するための化合物 | |
| CA3231001A1 (en) | Methods for treating neurogenerative diseases | |
| US20180258083A1 (en) | Inhibitors of lrrk2 kinase activity | |
| CA3230996A1 (en) | Methods for treating neurogenerative diseases | |
| WO2023039369A1 (en) | Methods for treating neurogenerative diseases | |
| US20240051968A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US20240041886A1 (en) | Methods for treating spinocerebellar ataxia type 3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241015 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R114 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF METHOD OF CORRESPONDENCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250820 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250820 |